FineHeart Completes First Successful Chronic In-Vivo Study of its ICOMS Device Intended for the Treatment of Severe Heart Failure
Retrieved on:
Tuesday, May 5, 2020
Medical devices, Health, Surgery, Clinical trials, Cardiology, Biotechnology, Medicine, Medical specialties, Medical technology, Prosthetics, Biomedical engineering, Cardiac surgery, Cardiac electrophysiology, Implant, Tissue engineering, Thoracotomy, Heart failure, Cardiopulmonary bypass, ICOMS, FineHeart – www.fine-heart.com
The results of this preliminary chronic study are extremely promising and set the stage for the next phase of the products development.
Key Points:
- The results of this preliminary chronic study are extremely promising and set the stage for the next phase of the products development.
- Heart failure (HF) is the second leading cause of death in the U.S. and Europe.
- The ability to support natural heart function through a fully implantable, permanent device would dramatically improve heart failure patient quality of life and long-term outcomes.
- Simple surgery with implant stability: ICOMS is implanted via mini-thoracotomy through a trans-apical approach into the beating heart without cardiopulmonary bypass.